evipedia.ai ← Back

Piceatannol for Health & Longevity

Evidence Review created on 07/30/2026 using AI4L / Opus 4.8

Also known as: 3,3’,4,5’-Tetrahydroxystilbene, 3,4,3’,5’-Tetrahydroxy-trans-stilbene, PIC, Astringinin, trans-Piceatannol

Motivation

Piceatannol is a natural plant compound, a close chemical cousin of resveratrol, the polyphenol made famous by red wine and grapes. It carries one extra oxygen-bearing group on its structure, and that small difference makes it a stronger antioxidant and, in laboratory work, a more active molecule than its better-known relative. The richest dietary source is the seed of the passion fruit, though it also appears in grapes, white tea, sugarcane, blueberries, and the herb known as nut grass.

Interest in piceatannol grew out of the search for a “better resveratrol.” Laboratory and animal studies pointed to effects on blood sugar handling, fat burning, and the activity of proteins linked to healthy aging. A handful of small human trials, several using passion-fruit-seed extract, have since explored its effects on insulin, skin moisture, and a longevity-associated protein called sirtuin 1. Much of this human work has been sponsored by a single food company, so the findings are promising but preliminary.

This review examines what is actually known about piceatannol: how it works in the body, the benefits and risks suggested by the evidence, the doses used in human studies, and where the science remains uncertain.

Benefits - Risks - Protocol - Conclusion

This section lists high-quality overview resources that discuss piceatannol and its biology in substantial depth.

Note: No content from the priority experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, or Life Extension) could be found, as none of these platforms appear to cover piceatannol specifically. The items above are the highest-quality overview sources identified.

Grokipedia

Piceatannol

The Grokipedia entry provides a broad reference overview of piceatannol’s chemistry, natural sources, pharmacology, and researched biological activities, serving as a general orientation to the compound.

Examine

No dedicated Examine article for piceatannol was found. Examine.com does not currently maintain a standalone supplement page for this compound.

ConsumerLab

No dedicated ConsumerLab article or product test for piceatannol was found. ConsumerLab does not currently review piceatannol as a standalone supplement category.

Systematic Reviews

No systematic reviews or meta-analyses for Piceatannol were found on PubMed as of 07/30/2026.

Mechanism of Action

Piceatannol is a stilbene polyphenol (molecular formula C₁₄H₁₂O₄, molecular weight 244.24 g/mol) that differs from resveratrol by a single additional hydroxyl (oxygen-and-hydrogen) group, giving it a catechol (a paired-hydroxyl chemical motif) that increases its antioxidant strength. Its actions are best understood as a network of overlapping effects rather than a single target.

  • Direct antioxidant and antioxidant-gene activation: The catechol group lets piceatannol quench reactive oxygen species (unstable, cell-damaging molecules) directly, reportedly with several-fold greater potency than resveratrol. It also switches on Nrf2 (a master regulator of the cell’s antioxidant defenses), raising the protective enzymes HO-1 (heme oxygenase-1) and NQO-1 (NAD(P)H quinone dehydrogenase-1, both antioxidant enzymes).

  • Sirtuin and energy-sensing pathways: Piceatannol raises expression of SIRT1 (sirtuin 1, a longevity-associated protein that senses cellular energy) and activates AMPK (AMP-activated protein kinase, the cell’s fuel gauge). Through SIRT1 it de-represses PGC-1α (a master switch for building new mitochondria), increasing mitochondrial number and fat-burning gene activity in muscle cells.

  • Glucose handling: In muscle-cell studies piceatannol promotes GLUT4 (the muscle glucose transporter) movement to the cell surface even without insulin, and it inhibits intestinal α-glucosidase (a carbohydrate-digesting enzyme), together lowering post-meal blood sugar.

  • Blood-vessel and nitric-oxide effects: Piceatannol increases eNOS (endothelial nitric oxide synthase, the enzyme that makes the vessel-relaxing molecule nitric oxide), inhibits arginase and activates DDAH (an enzyme that clears ADMA, asymmetric dimethylarginine — a natural blocker of nitric-oxide production), collectively favoring vessel relaxation.

  • Anti-inflammatory and immune signaling: It suppresses NF-κB (a master switch controlling inflammation genes) and COX-2 (cyclooxygenase-2, an inflammation-driving enzyme), and it is a well-characterized inhibitor of Syk (spleen tyrosine kinase, a signaling enzyme central to immune-cell activation) and of JAK1 (a cytokine-signaling enzyme).

  • Hormone-receptor activity: Piceatannol behaves as a phytoestrogen (a plant compound that weakly mimics estrogen), binding estrogen receptors and the GPER (G protein-coupled estrogen receptor); this underlies some of its fat-cell and skin effects but also a theoretical hormonal caution.

Competing mechanistic views exist. The SIRT1 story is the clearest example: laboratory and one large human study show piceatannol raising sirtuin 1 activity, whereas a separate human trial found no change in this protein in blood immune cells, suggesting the effect may be tissue-, dose-, or population-specific rather than universal.

Pharmacological properties. Piceatannol is not a licensed drug but a dietary compound. Its oral bioavailability is low: after absorption it is rapidly conjugated (chemically tagged for excretion) by glucuronidation and sulfation in the gut and liver, so little of the free compound reaches the bloodstream, and its half-life is short (on the order of hours). It is metabolized mainly by phase II conjugating enzymes (UGTs and SULTs), with a methylated metabolite, isorhapontigenin, that is itself active. Notably, the enzyme CYP1B1 (a tissue drug-and-chemical-processing enzyme) converts resveratrol into piceatannol in the body. Tissue distribution is limited by this rapid metabolism, and manufacturer-linked animal work suggests piceatannol reaches somewhat higher blood levels than resveratrol when the two are compared head-to-head.

Historical Context & Evolution

Piceatannol was first characterized as a naturally occurring stilbene of the grapevine and related plants, and for much of the twentieth century it was of interest chiefly to plant chemists studying Vitis vinifera (grape) and Japanese knotweed. Source plants such as sugarcane and passion fruit have long dietary and folk-medicine histories, but piceatannol itself was not the focus of that traditional use.

Its first prominent scientific role was as a laboratory tool: piceatannol became a standard pharmacological inhibitor of Syk (spleen tyrosine kinase) in immunology research, used to probe immune-cell signaling rather than as a therapy. Interest in its own therapeutic potential grew as resveratrol rose to fame in the 1990s and 2000s; researchers noted that piceatannol is both a structural analog and an in-body metabolite of resveratrol (formed by the enzyme CYP1B1) and asked whether its extra hydroxyl group made it more potent.

The reasons it came to be considered for health optimization are therefore twofold: the broader “stilbene and sirtuin” enthusiasm around resveratrol, and the practical discovery that passion-fruit seeds — an abundant food-industry by-product — are an unusually rich source. This drove a wave of preclinical studies on metabolism, blood vessels, skin, and cancer, followed since roughly 2017 by small human trials of passion-fruit-seed piceatannol.

The early preclinical findings on glucose handling, fat metabolism, and antioxidant activity have not been overturned, but they also have not been confirmed by large human trials; the current standing is that the mechanistic and animal case is substantial while the human case remains early and largely industry-generated. What changed over time is not that early work was discredited, but that the field recognized how much the poor bioavailability of stilbenes limits translation from cells to people — a caution that applies to piceatannol as much as to resveratrol.

Expected Benefits

The benefits below are graded by the strength of the underlying evidence. For piceatannol, no benefit is supported by large, independent, long-term human trials, so no benefit reaches the “High” tier. A dedicated search of clinical and expert sources was performed to confirm the benefit profile is complete.

Medium 🟩 🟩

Skin Hydration and Wrinkle Reduction

Oral piceatannol from passion-fruit seed appears to improve skin moisture and reduce fine wrinkles in women. The proposed mechanism is SIRT1-mediated: piceatannol raises collagen production and hyaluronic-acid synthesis in skin cells while suppressing the collagen-degrading enzymes MMPs (matrix metalloproteinases). This is the most consistently replicated human benefit, supported by two randomized, double-blind, placebo-controlled trials in Japanese women. Both trials were small, short (8 weeks), and funded by a passion-fruit-seed-extract manufacturer, and one pre-selected participants with low baseline skin hydration, which limits how far the results generalize.

Magnitude: In an 8-week trial (10 mg/day, 82 women), the piceatannol group showed a statistically significant increase in stratum-corneum hydration on two independent devices and a significant improvement in crow’s-feet wrinkle grade versus placebo (effect size ~0.64 for hydration).

Low 🟩

Insulin Sensitivity and Glycemic Control

In a small randomized trial, piceatannol improved fasting insulin and an insulin-resistance index — but only in the overweight-men subgroup, with no effect in non-overweight men or in women. Mechanistically this fits animal and cell data showing insulin-independent glucose uptake, α-glucosidase inhibition, and AMPK activation. The evidence is graded Low because it rests on a single small trial (39 participants total) driven by a subgroup finding, with no confirmation in a larger population.

Magnitude: In overweight men, an insulin-resistance index (HOMA-IR, a fasting blood estimate of insulin resistance) fell about 17% on piceatannol versus a ~31% rise on placebo over 8 weeks at 20 mg/day; fasting insulin dropped from ~8.3 to ~6.7 µU/mL.

Blood Pressure and Heart Rate Reduction

The same trial found lower blood pressure and resting heart rate after piceatannol, again only in overweight men. Proposed mechanisms include improved nitric-oxide signaling and reduced sympathetic (fight-or-flight) drive, though the trial itself found no change in a direct test of blood-vessel function. The grade is Low for the same reasons: one small trial, subgroup-limited, not independently replicated.

Magnitude: In overweight men over 8 weeks, systolic blood pressure fell from ~131 to ~121 mmHg, diastolic from ~86 to ~77 mmHg, and heart rate from ~68 to ~59 beats per minute.

SIRT1 Activation and Fat Metabolism ⚠️ Conflicted

Piceatannol raises SIRT1 (sirtuin 1) activity and fat-burning gene programs in muscle cells and, in one large human study, in whole blood — a pathway of direct interest to longevity readers because sirtuins are linked to mitochondrial health and energy metabolism. The evidence is conflicted: one human trial (100 mg/day) found significantly higher SIRT1 gene expression in blood, most clearly in older and higher-body-weight participants, while a separate human trial found no change in this protein in isolated blood immune cells. Earlier manufacturer studies also report modest increases in fat oxidation. The grade is Low because the outcome measured is a molecular marker, not a hard clinical endpoint, and human results disagree.

Magnitude: Significant increase in SIRT1 messenger-RNA in whole blood after 1 week at 100 mg/day (largest in adults aged 60–69 and those with high body-mass index); no significant change reported at a 20 mg/day dose in a different trial.

Speculative 🟨

Antioxidant and Anti-inflammatory Activity

Piceatannol is a potent direct antioxidant and activates the body’s own antioxidant defenses (Nrf2/HO-1/NQO-1) while suppressing inflammatory signaling (NF-κB, COX-2) in laboratory systems. Whether this translates into meaningful clinical benefit is unproven: the one human trial that measured inflammation and oxidative-stress blood markers found no significant change. The basis for a clinical claim is therefore mechanistic and cell-based only.

Cardiovascular and Endothelial Protection

Beyond the blood-pressure signal above, piceatannol shows anti-atherosclerotic, cholesterol-lowering, and vessel-relaxing effects in animal and cell studies, including enhancement of nitric-oxide production. No dedicated human cardiovascular-outcome or endothelial-function trial has confirmed these effects; the evidence is preclinical.

Anticancer and Chemopreventive Potential

An extensive preclinical literature reports that piceatannol slows growth and triggers programmed cell death in many cancer cell lines and animal models, through cell-cycle arrest, caspase activation, and NF-κB and Syk inhibition. There are no human cancer-treatment or cancer-prevention trials, so this remains entirely hypothesis-generating; a paradoxical estrogen-receptor stimulation of some hormone-dependent cancer cells has also been reported in vitro.

Neuroprotection

Reviews describe piceatannol protecting nerve cells against oxidative and amyloid-related damage and modulating inflammation in brain-cell and animal models, prompting interest for cognitive aging. This is based on mechanistic and animal data only, with no human neurological trials.

Benefit-Modifying Factors

  • Body-weight and metabolic status: The clearest modifier. In the main human trial, improvements in insulin sensitivity, blood pressure, and heart rate appeared only in overweight men, not in lean men or in women, suggesting benefits may be limited to those with existing metabolic strain.

  • Sex and hormonal status: Effects differed by sex in human studies, and the SIRT1 response was reported most clearly in women and postmenopausal participants in one trial, consistent with piceatannol’s phytoestrogen activity. Sex-based responses appear real but are not yet predictable.

  • Age: The blood SIRT1 response was strongest in adults aged 60–69, and sirtuin activity naturally declines with age, so older individuals at the upper end of the target range may in principle respond more — though this rests on subgroup data.

  • Baseline biomarker levels: Higher baseline fasting insulin, blood pressure, or (for skin studies) low baseline skin hydration were associated with larger measured changes, i.e., those starting further from optimal had the most to gain.

  • Genetic variation in metabolism: Because piceatannol is heavily processed by conjugating enzymes (UGTs and SULTs) and interacts with CYP1B1, individual differences in these enzymes could plausibly affect how much active compound circulates, though this has not been directly studied in humans.

Potential Risks & Side Effects

Human safety data come only from small, short trials at 10–100 mg/day, in which piceatannol was well tolerated. The risks below are therefore dominated by theoretical and laboratory-based concerns rather than documented human harms. A dedicated search of drug-reference and toxicology sources was performed to confirm the profile is complete.

Low 🟥

Mild Gastrointestinal and Transient Adverse Events

Across the human trials, reported adverse events were mild and generally judged unrelated to piceatannol, including occasional gastrointestinal discomfort, headache, and transient skin symptoms such as hives. No serious adverse events attributable to piceatannol have been reported at supplement doses. The main caveat is that total human exposure is small and short-term.

Magnitude: In a trial of ~300 adults taking 100 mg/day, 24 adverse events occurred in 23 participants with no serious events, and rates did not differ meaningfully from placebo; two transient hives cases (one on piceatannol, one on placebo) were considered possibly product-related.

Speculative 🟨

Increased Bleeding Tendency (Antiplatelet Effect)

Stilbenes including piceatannol inhibit platelet aggregation in laboratory studies, partly through Syk inhibition, raising a theoretical risk of easier bruising or bleeding, especially alongside blood-thinning medication. No human bleeding events have been reported, so this is a mechanism-based caution only.

Estrogenic (Phytoestrogen) Activity

Piceatannol binds estrogen receptors and can stimulate the growth of estrogen-dependent cells in vitro. For people with hormone-sensitive conditions this is a theoretical concern, though the weak, dietary-level exposure and lack of human signal make its real-world importance unknown.

Drug-Metabolizing Enzyme Inhibition and Interactions

Piceatannol inhibits certain cytochrome P450 enzymes (notably CYP1A1 and CYP1B1) and competes for conjugating enzymes in laboratory systems, which could in theory alter the levels of co-administered drugs. This has not been demonstrated to cause clinically relevant interactions in humans.

Unknown Long-Term Safety and Genotoxicity Signals

A toxicology review noted that piceatannol produces cytotoxicity and DNA damage in some cell assays at high concentrations, that it can act as a pro-oxidant in the presence of copper, and that it has not been evaluated with the standard in-vivo genotoxicity and chronic-toxicity tests required for food additives. Long-term human safety is therefore genuinely unestablished.

Immune Modulation via Syk Inhibition

Because piceatannol inhibits spleen tyrosine kinase, a central immune-signaling enzyme, sustained high intake could in principle dampen aspects of immune or allergic signaling. This is entirely theoretical at dietary or supplement doses and has not been observed clinically.

Risk-Modifying Factors

  • Concurrent medication use: The most relevant modifier. People on blood thinners, antiplatelet agents, blood-pressure medication, or blood-sugar-lowering drugs face the greatest theoretical risk of additive effects (bleeding, low blood pressure, or low blood sugar).

  • Hormone-sensitive conditions: Given the phytoestrogen activity, individuals with a history of estrogen-sensitive cancers or on hormone therapy may warrant more caution, though evidence of real harm is absent.

  • Sex and hormonal status: Piceatannol’s estrogen-receptor activity means its biological effects — desirable or not — may differ between men, premenopausal women, and postmenopausal women.

  • Genetic variation in metabolism: Because piceatannol is cleared by conjugating enzymes (UGTs and SULTs) and interacts with CYP1B1, individuals whose genetic makeup gives slower conjugation or altered CYP1B1 activity could in principle sustain higher circulating levels of the active compound — and therefore greater exposure to the theoretical bleeding, hormonal, and enzyme-inhibition concerns — though this has not been studied directly in humans.

  • Baseline biomarker levels: Baseline measures of organ function and coagulation can flag who is more susceptible to the theoretical risks: elevated baseline liver enzymes (ALT/AST) or reduced kidney function (eGFR) signal reduced clearance capacity, and an already-prolonged clotting profile or low platelet count would amplify the theoretical antiplatelet caution.

  • Pre-existing liver or kidney impairment: Because piceatannol is cleared by hepatic conjugation and renal excretion, impaired organ function could alter exposure; the human trials specifically excluded such participants, so data are lacking.

  • Age: Older adults are more likely to be on interacting medications and to have age-related organ changes, indirectly raising interaction risk even though piceatannol itself was well tolerated in the age ranges studied.

Key Interactions & Contraindications

  • Anticoagulant and antiplatelet drugs (warfarin, apixaban, clopidogrel, aspirin): Caution — theoretical additive antiplatelet effect could increase bleeding risk. Separation of dosing does not mitigate a pharmacodynamic overlap; monitoring for bruising or bleeding is prudent.

  • Antidiabetic drugs (metformin, sulfonylureas such as glipizide, insulin): Caution — piceatannol’s glucose-lowering actions could add to these agents and, with insulin or sulfonylureas, theoretically contribute to low blood sugar. Glucose monitoring is the sensible mitigation.

  • Antihypertensive drugs (ACE inhibitors such as lisinopril, calcium-channel blockers such as amlodipine): Caution — possible additive blood-pressure lowering, most plausible in overweight individuals in whom piceatannol showed a blood-pressure effect. Monitor blood pressure.

  • Over-the-counter medications (NSAIDs such as ibuprofen, aspirin): Caution — shared antiplatelet and gastrointestinal effects could compound bleeding risk.

  • Supplements with blood-thinning or additive effects: Supplement interactions include fish oil, vitamin E, ginkgo, garlic, and other polyphenols (resveratrol, quercetin) that also inhibit platelets or activate sirtuins — additive antiplatelet or metabolic effects are plausible. These are the supplements most likely to have additive effects with piceatannol.

  • CYP-metabolized drugs: Caution — because piceatannol inhibits CYP1A1/CYP1B1 and related enzymes in vitro, drugs heavily dependent on these pathways could theoretically accumulate; clinical relevance is unproven.

  • Populations who should avoid or seek guidance before use: Pregnant or breastfeeding women (no safety data and phytoestrogen activity); individuals with hormone-sensitive cancers; people with bleeding disorders or scheduled for surgery (typically stop 1–2 weeks beforehand as a general antiplatelet-supplement precaution); and children — none of whom were represented in the trials.

Risk Mitigation Strategies

  • Start at a low, food-derived dose: Beginning at the low end of the studied range (10 mg/day) rather than high experimental doses limits exposure to a level shown to be well tolerated, mitigating the unknown-long-term-safety and enzyme-interaction concerns.

  • Perioperative and bleeding precautions: Discontinuing piceatannol 1–2 weeks before any scheduled surgery or invasive procedure mitigates the theoretical additive antiplatelet bleeding risk.

  • Monitor when combined with metabolic medications: For anyone on blood-pressure or blood-sugar-lowering therapy, periodic home monitoring of blood pressure and, where relevant, glucose mitigates the risk of additive low readings.

  • Avoid in hormone-sensitive and pregnancy settings: Not using piceatannol during pregnancy, breastfeeding, or with a history of estrogen-sensitive cancer directly avoids the phytoestrogen-related concern until human data exist.

  • Choose tested, single-ingredient products: Selecting third-party-tested passion-fruit-seed extracts with a stated piceatannol content mitigates the risk of contaminants or mislabeled dosing that would otherwise make exposure unpredictable.

  • Separate from narrow-therapeutic-index drugs: For those taking medications sensitive to metabolism changes, spacing intake and reviewing the combination with a clinician mitigates the theoretical enzyme-inhibition interaction.

Therapeutic Protocol

Piceatannol has no standardized medical protocol; the “protocol” below is reconstructed from the doses and formulations used in published human trials, most of which used passion-fruit-seed extract and were run by researchers linked to a single Japanese food company (Morinaga & Co.).

  • Typical studied dose: Human trials have used 10 mg/day (skin outcomes), 20 mg/day (metabolic outcomes), and up to 100 mg/day (sirtuin/fat-metabolism outcomes) of piceatannol, generally standardized from passion-fruit-seed extract. There is no established optimal dose, and the most effective dose remains explicitly unresolved in the literature.

  • Source and formulation: The best-characterized form is piceatannol purified from passion-fruit (Passiflora edulis) seed, sometimes complexed with gamma-cyclodextrin to aid stability and absorption. Whole passion-fruit-seed extract and Cyperus rotundus (nut grass) extract are alternative delivery formats studied in humans.

  • Competing approaches: Some longevity users take piceatannol as a presumed “upgraded resveratrol” for sirtuin activation, while others obtain it as part of a whole passion-fruit-seed extract for combined skin and metabolic effects; neither approach is established as superior, and both are presented here without endorsement.

  • Best time of day: Trials dosed once daily, often in the evening or with/after a meal; no comparative timing study exists, so an evening or with-food schedule simply follows the trial precedent and may modestly aid absorption of a fat-soluble polyphenol.

  • Half-life and dosing frequency: Piceatannol has a short half-life (hours) and is rapidly conjugated, so blood levels are transient. One trial split 20 mg into twice-daily dosing to maintain exposure, while others used once-daily; splitting the dose is a reasonable way to offset the short half-life, though no study has compared single versus split dosing for outcomes.

  • Genetic considerations: No pharmacogenetic guidance exists. Variation in conjugating enzymes (UGT, SULT) and CYP1B1 could theoretically influence exposure, but no genotype-guided dosing has been studied.

  • Sex-based differences: Human responses differed by sex (metabolic effects seen in men, some SIRT1 effects clearer in women/postmenopausal participants), so response cannot be assumed uniform across sexes.

  • Age-related considerations: Older adults showed the clearest blood SIRT1 response in one trial; there is no evidence requiring dose adjustment for age, but older users are more likely to be on interacting medications.

  • Baseline biomarker considerations: The metabolic benefits concentrated in those with higher baseline insulin and blood pressure, so response is likely greater in people starting with suboptimal metabolic markers.

  • Pre-existing conditions: Trials excluded people with significant liver, kidney, heart, or endocrine disease, so the studied protocol applies to generally healthy adults; those with such conditions have no evidence base to draw on.

Discontinuation & Cycling

  • Lifelong versus short-term: Piceatannol is a dietary compound, not a treatment for a defined condition, so there is no established course length; human trials ran only 1–8 weeks, and whether continued use is needed to sustain any effect is unknown.

  • Withdrawal effects: No withdrawal syndrome has been described. Given the short half-life and reversible mechanisms, abrupt discontinuation would not be expected to cause rebound effects, though any modest metabolic benefit would presumably fade.

  • Tapering: No tapering is required or has been studied; the compound can reasonably be stopped without a taper.

  • Cycling: No evidence addresses whether cycling maintains efficacy or prevents tolerance. Because effects appear tied to ongoing exposure rather than to receptor down-regulation, there is no mechanistic reason cycling would be necessary, but this is untested.

Sourcing and Quality

  • Primary source material: The most studied commercial source is piceatannol from passion-fruit (Passiflora edulis) seed, an abundant food-industry by-product; other sources include grapes, sugarcane, and Cyperus rotundus. Products vary widely in whether they list a standardized piceatannol content versus a generic “passion fruit seed extract.”

  • What to look for: Choose products stating the actual milligrams of piceatannol per serving and, ideally, the extract’s standardization percentage, since whole-seed extracts contain only a fraction of piceatannol alongside other stilbenes such as scirpusin B.

  • Third-party testing: Because piceatannol is a niche botanical extract with limited regulatory oversight, third-party testing (for identity, piceatannol content, and contaminants such as heavy metals and solvent residues) is important; independent verification seals (e.g., NSF, USP, or Informed Choice) add assurance.

  • Formulation quality: Gamma-cyclodextrin-complexed or otherwise absorption-optimized forms have the most direct trial support; simple bulk-powder products may deliver less bioavailable compound given piceatannol’s inherently poor absorption.

  • Reputable formats: Standardized passion-fruit-seed-extract ingredients (such as the branded material used in the Japanese human trials) are the most evidence-aligned; single-ingredient piceatannol from established supplement manufacturers with published certificates of analysis is preferable to unbranded bulk powder.

Practical Considerations

  • Time to effect: Effects in trials emerged over weeks — SIRT1 changes within about 1 week, and metabolic and skin changes over 4–8 weeks — so any benefit is gradual, not acute.

  • Common pitfalls: The commonest mistakes are expecting resveratrol-level research backing (piceatannol has far less human data), confusing whole passion-fruit-seed extract with a standardized piceatannol dose, and assuming the metabolic benefits seen only in overweight men apply to everyone.

  • Regulatory status: Piceatannol is sold as a dietary supplement / food ingredient, not an approved drug; it is not FDA-approved for any condition and has not completed the standard food-additive safety evaluations noted by European regulators, so all use is essentially off-label self-experimentation.

  • Cost and accessibility: Standardized piceatannol products are relatively niche and can be more expensive and harder to find than mainstream resveratrol, though neither cost nor access is prohibitive; cost is a secondary consideration to the limited efficacy evidence.

Interaction with Foundational Habits

  • Sleep: Interaction direction is largely unknown (likely neutral). No trial reported sleep effects, and piceatannol has no known stimulant activity; the theoretical SIRT1/circadian link is speculative, and no practical timing precaution is established for sleep.

  • Nutrition: Direct, potentially potentiating. As a fat-soluble polyphenol with poor absorption, piceatannol is reasonably taken with a meal containing some fat to aid uptake; its glucose- and fat-metabolism effects may be most relevant against a background of caloric excess, and a diet already rich in polyphenols provides overlapping stilbenes. No foods need to be avoided.

  • Exercise: Indirect and potentially complementary. Piceatannol’s proposed actions — SIRT1/PGC-1α activation and mitochondrial biogenesis — overlap with adaptations to endurance exercise; whether it adds to or, like high-dose antioxidants, could blunt exercise adaptations is untested, so pairing it with training is neither clearly beneficial nor clearly harmful.

  • Stress management: Largely neutral/indirect. There is no evidence piceatannol affects the cortisol or stress-hormone axis in humans; a mood questionnaire in one trial showed no change, so no specific stress-related interaction or practical consideration is established.

Monitoring Protocol & Defining Success

Because piceatannol’s plausible benefits are metabolic and vascular, baseline and follow-up testing centers on glucose, insulin, blood pressure, and lipids. Baseline testing should be done before starting, ideally fasting, to establish personal reference points against which to judge any change.

Ongoing monitoring can follow a simple cadence: recheck relevant markers at about 8 weeks (matching the trial duration), then every 6–12 months if use continues, with home blood-pressure checks weekly to monthly for anyone with elevated readings or on blood-pressure medication.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting insulin 2–6 µU/mL Primary metabolic target; piceatannol lowered it in overweight men Fasting sample; pairs with fasting glucose to compute insulin resistance (HOMA-IR, a fasting estimate of insulin resistance). Conventional labs often flag only >25 µU/mL
Fasting glucose 75–90 mg/dL Screens glucose handling, the main studied metabolic effect Fasting required; conventional “normal” extends to 99 mg/dL, higher than the functional target
HbA1c < 5.4% Reflects 3-month average blood sugar No fasting needed; conventional prediabetes cutoff is 5.7%, above the functional optimum
Blood pressure < 120/80 mmHg Piceatannol reduced it in overweight men; easy at-home tracking Measure seated after 5 min rest; average several readings; time of day matters
Resting heart rate 50–70 bpm Fell alongside blood pressure in the trial Best measured at rest or via a wearable on waking
Lipid panel (LDL-C, HDL-C, triglycerides) Triglycerides < 100 mg/dL; HDL-C > 50 mg/dL Cardiovascular context; preclinical cholesterol effects claimed LDL-C (low-density lipoprotein cholesterol) and HDL-C (high-density lipoprotein cholesterol); fasting preferred for triglycerides; no human lipid benefit is proven
hs-CRP < 1.0 mg/L Tracks inflammation, a proposed target hs-CRP (high-sensitivity C-reactive protein, an inflammation marker); avoid testing during acute illness; pairs well with a metabolic panel
ALT / AST (liver enzymes) ALT < 25 U/L (men), < 20 U/L (women) Basic safety given hepatic metabolism Conventional upper limits (~40 U/L) are higher than functional targets

Qualitative markers of success include:

  • Energy levels and perceived vigor through the day
  • Skin hydration, smoothness, and appearance (the most replicated benefit)
  • Absence of new bruising or bleeding (a safety signal)
  • General well-being and mood stability

Success is best defined conservatively: for a metabolically at-risk user, a meaningful fall in fasting insulin or blood pressure toward the functional ranges above; for a skin-focused user, measurable improvement in hydration or wrinkle appearance. Absence of any measurable change after 8–12 weeks is a reasonable signal that the compound is not delivering benefit for that individual.

Emerging Research

  • First-in-human safety trial of a piceatannol derivative: A Phase 1 dose-escalation study is registered for an intravenous glycolic-acid-substituted piceatannol compound (TGKP) in healthy volunteers, aimed at acute respiratory distress syndrome, testing tolerability and pharmacokinetics across ascending doses (NCT06127381, Phase 1, 25 healthy volunteers). It signals pharmaceutical interest in piceatannol-based molecules, though it studies a synthetic derivative, not the dietary compound.

  • Inflammation/aging intervention including piceatannol: A registered intervention trial using an inflammatory-age biomarker included piceatannol among its components but was terminated (NCT04983017, 781 participants, terminated), so it will not yield efficacy data; it is noted for completeness rather than as supporting evidence.

  • Bioavailability enhancement: A major research direction is overcoming piceatannol’s poor absorption through nanoparticle and delivery-system approaches, which could change whether the mechanistic promise translates to humans (Zhang et al., 2026 on passion-fruit-seed piceatannol for skin-targeted delivery). Success here could strengthen the case; failure would reinforce that oral dosing is limiting.

  • Dietary-stilbene and cancer epidemiology: Prospective cohort work on dietary stilbene intake and cancer risk is emerging and could either support or undercut population-level relevance of stilbenes like piceatannol (Na et al., 2026, two prospective cohorts on dietary stilbenes and lung-cancer risk).

  • Independent toxicology and long-term safety: Reviewers have called for the standard in-vivo genotoxicity, subchronic, and carcinogenicity studies that piceatannol still lacks (Medrano-Padial et al., 2021). This is the research most likely to weaken the case if adverse signals emerge, and its absence is itself a key uncertainty.

  • Larger, independent human efficacy trials: The field’s central gap is the absence of large, adequately powered, independently funded human trials for any endpoint; future glucose-, cardiovascular-, or skin-focused trials not tied to a single manufacturer are needed before benefits can be graded higher.

Conclusion

Piceatannol is a natural relative of resveratrol, found most abundantly in passion-fruit seeds, that behaves as a strong antioxidant and touches many of the pathways tied to metabolism and healthy aging. Laboratory and animal work is genuinely rich, pointing to effects on blood sugar, fat burning, blood vessels, skin, and a longevity-linked protein. In people, however, the evidence is still thin. The most repeatable human finding is modest improvement in skin moisture and fine wrinkles; small trials also hint at better insulin and blood-pressure readings, but only in overweight men, and effects on the longevity protein disagree between studies.

An important caveat is that most human trials have been small, short, and run by researchers tied to a single company that sells the extract, so the results should be read as promising rather than settled. Piceatannol has been well tolerated at the low doses studied, but its long-term safety has not been formally tested, and several cautions — easier bleeding, mild hormone-like activity, and possible interactions with medications — rest on laboratory findings.

For a health- and longevity-minded reader, piceatannol sits in the “biologically interesting, humanly unproven” category: a plausible compound whose real value in people remains undemonstrated. Where the evidence is uncertain, that uncertainty is real.

Top - Benefits - Risks - Protocol